Sutro Biopharma, Inc. (STRO) Dividend History

Company News

• New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty

  The article discusses the rise in cancer incidence and the need for better treatments, as well as the potential impact of budget reductions and new tariffs on innovation. Several oncology companies, including Oncolytics Biotech, Sutro Biopharma, BriaCell Therapeutics, and Tempus AI, have reported notable updates in 2025.

  Benzinga

  Featured Companies: BCTX ONCY TEM
• Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

  Sutro Biopharma presented data from the dose-optimization portion of the REFRαME-O1 trial for luveltamab tazevibulin (luvelta) in patients with platinum resistant ovarian cancer. The data showed encouraging antitumor activity and a consistent safety profile across dose levels.

  GlobeNewswire Inc.
• Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players

  The oncology industry has seen significant progress, with cancer deaths falling by 33% in the last 30 years. Several key players, including Oncolytics Biotech, Novartis, Lantheus Holdings, Sutro Biopharma, and Zymeworks, have reported promising developments in their cancer research and treatments.

  Benzinga

  Featured Companies: LNTH ONCY ZYME
• Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024

  Sutro Biopharma, a clinical-stage oncology company, will host a Research Forum to highlight its pipeline of next-generation antibody drug conjugates (ADCs) on October 10, 2024.

  GlobeNewswire Inc.
• Spruce Biosciences, Inc. (SPRB) Reports Q1 Loss, Tops Revenue Estimates

  Spruce Biosciences (SPRB) delivered earnings and revenue surprises of 12.50% and 79.55%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

  Zacks Investment Research